Skip to content

RESTORE in Patients Who Had COVID-19 and Close Others

RESTORE: An Online Self-directed Mental Health Intervention for Individuals Who Had COVID-19 and Close Others

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04958902
Enrollment
20
Registered
2021-07-12
Start date
2021-10-22
Completion date
2021-11-01
Last updated
2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depressive Symptoms, Mental Health, PTSD

Brief summary

There is considerable need for psychological intervention targeting stressor-related mental health symptoms related to COVID-19. The investigators have developed an online self-directed transdiagnostic intervention to address this need called RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health. The specific aims of this project are to refine and investigate the initial safety, efficacy, and desirability of RESTORE for addressing mental-health symptoms in individuals who have recovered from severe COVID-19 and close others.

Detailed description

This uncontrolled pilot interventional study will examine the feasibility and preliminary efficacy of RESTORE. RESTORE is a guided self-directed online intervention to improve anxiety, depression, and posttraumatic stress disorder (PTSD) in individuals exposed to COVID-19 related traumatic or extreme stressors. RESTORE is based on evidence-based psychotherapies and has been designed to overcome many of the barriers associated with accessing evidence-based psychotherapies. The intervention will be iteratively refined over the course of the study. The guidance methods will also be refined over the course of the study The primary hypotheses are that RESTORE will be safe, feasible, and desirable to participants, and will lead to improvements in mental health symptom severity from baseline to post-intervention. Secondary hypotheses are that RESTORE will lead to significant improvements in perceived health, quality of life, and functioning that will be maintained at one-month follow-up. Participants will be assessed at baseline, pre-intervention, during the intervention (after module 4), immediately after the intervention, and 1 month after completion of the intervention.

Interventions

RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.

Sponsors

Toronto Metropolitan University
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Experienced a traumatic or extremely stressful experience related to being COVID-19+ or having a close other who was COVID-19+ * Participants who were COVID+ will be eligible once they are no longer exhibiting COVID-19 symptoms and those who were hospitalized will be eligible post-discharge * Close others will be eligible once their close other with COVID-19 has recovered or if their loved one is deceased * ≥ 18 years of age * Scores at above clinical threshold on at least one of: Patient Health Questionnaire-9 (\[PHQ-9\] score ≥ 10), Generalized Anxiety Disorder Scale-7 (\[GAD-7\] score ≥ 10), and/or Posttraumatic Stress Disorder Scale-5 (\[PCL-5\] score ≥ 33) * Access to a computer or a tablet with high speed internet access, be able to clearly see the screen of a computer or tablet, and be fluent in English * Ability to provide consent

Exclusion criteria

* Elevated risk of suicide * Currently enrolled in another intervention or treatment (e.g., cognitive behavioural therapy) for stress responses related to the COVID-19 pandemic

Design outcomes

Primary

MeasureTime frameDescription
Change in self-reported Post Traumatic Stress Disorder (PTSD) symptomsBaseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upThe PTSD Checklist-5 (PCL-5); Weathers, Litz, Keane, Palemeri, Marx, & Schnurr, 2013) weekly version will provide a measure of change in self-reported PTSD symptoms over the course of intervention. Items are rated from 0 (not at all) to 4 (extremely). Items are summed to create a total score ranging from 0 to 80. A cutoff score of ≥ 33 can be used for screening for PTSD diagnosis (Weathers et al, 2013).
Change in Patient Health Questionnaire-9 (PHQ-9)Baseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upA self-report measure of depression symptoms. Each of the 9 items is rated on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day). Items are summed to produce a total severity score ranging from 0 to 27, with higher scores indicating greater symptom severity. PHQ-9 scores ≥ 10 are considered indicative of moderate levels of depression (Manea et al., 2011).
Change in Generalized Anxiety Disorder-7 (GAD-7)Baseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upA brief clinical measure to assess anxiety severity. Each item is rated on a 4-point scale from 0 (not at all) to 3 (nearly every day). A symptom severity score is calculated based on the sum of the 7 items, with scores ranging from 0 to 21. GAD-7 scores of 10 and 15 are the cut-off points for moderate and severe anxiety, respectively (Spitzer et., 2006).

Secondary

MeasureTime frameDescription
Change in Mental Health Seeking Attitudes/Intention ScaleBaseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upThe Mental Health Seeking Attitudes/Intention Scale is an adapted 3-item measure to assess attitudes toward seeking help from a mental health professional (Hammer, Parent, & Spiker, 2018). Each of the items is rated on a 7-point scale, ranging from 1 (definitely false) to 7 (definitely true).
Change in Perceived Health, Functioning, and Quality of Life (QOL)Baseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upSingle items will be used to measure perceived health, work functioning, and quality of life over the past month. Each item is rated on a 5-point scale, ranging from 1 (not at all satisfied/poor) to 5 (extremely satisfied/excellent).
Change in Trauma-Related Guilt Inventory (TRGI)Baseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upThe TRGI is a 32-item self-report questionnaire designed to measure guilt experienced as a result of surviving a traumatic event. The inventory includes three scales: guilt cognitions, distress, and global guilt scales.
Change in Adapted Brief Grief QuestionnaireBaseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upThe Adapted Brief Grief Questionnaire is a 5-item self-report measure for screening for complicated grief (Shear et al., 2006). The items deal with difficulty accepting the death, interference in current life, troubling thoughts related to the death, avoidance of reminders of the loss, and feeling distant from others. Each item is scored from 0 to 2 (0 = not at all, 1 = somewhat, 2 = a lot).
Change in Perceived emotional social supportBaseline, pre-intervention; during the intervention (after module 4); immediately after the intervention; 1-month follow-upPerceived Emotional Social Support is a single item measure of emotional of social support received in the past week from family and friends (Stappenbeck et al., 2015). The item is rated on a 5-point Likert scale, with responses ranging from 1 (strongly disagree) to 5 (strongly agree).

Other

MeasureTime frameDescription
Qualitative interviewsImmediately after the interventionQualitative interviews will be conducted post-intervention to further assess acceptability and to improve RESTORE content and presentation.
Client Satisfaction QuestionnaireImmediately after the interventionAt the end of the intervention, participants will complete the Client Satisfaction Questionnaire (Attkisson & Zwick, 1982), which measures client satisfaction with the intervention they received. This short questionnaire consists of 6 items, and each item is rated on a 4-point scale with varying response alternatives (1=poor/no, definitely not/quite dissatisfied to 4=excellent/yes, definitely/very satisfied).
Intervention engagementImmediately after the interventionEngagement will be measured by mean number of platform log-ins, mean number of module entries and mean number of practice assignment entries.
Intervention adherenceImmediately after the interventionAdherence to the intervention measured by mean number of completed modules and drop out rate.
Eligibility and enrolment ratesFrom screening through to study enrolment.Feasibility of recruitment measured by percentage of screened individuals who are eligible and percentage of those who screen eligible who are subsequently enrolled.

Countries

Canada

Contacts

Primary ContactKathryn Trottier, PhD
kathryn.trottier@uhn.ca4163404800
Backup ContactCandice Monson, PhD
candice.monson@ryerson.ca

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026